Thanks Comora - I am actually going to email JP and ask the question.
Little T mentioned that Flipper is in regular contact with the company, and I know that he/she posted about Dementia in September, saying that we should leverage the potential of 2591 as a treatment for Dementia/Parkinsons in any TO negotiations. It is obviously coincidental, given this study was only just published in the journal Neuron, but I am glad that someone closer to the company than I am, is at least suggesting this line of thinking.
NEU Price at posting:
$12.20 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)